Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 304-310

  Sen, Nihat ^a   Ozlu, Mehmet Fatih ^b   Akgul, Emin Ozgur ^c   Kanat, Selcuk ^b   Cayci, Tuncer ^c   Turak, Osman ^b   Yaman, Halil ^c   Sokmen, Erdogan ^b   Ozcan, Firat ^b   Maden, Orhan ^b   Demir, Ahmet Duran ^b   Covic, Adrian ^d   Kanbay, Mehmet ^c  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Yuksek Ihtisas Education and Research Hospital   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Asymmetric dimethylarginine; Percutaneous coronary intervention; Prognosis; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ARGININE; CLOPIDOGREL; N(G),N(G) DIMETHYLARGININE; TIROFIBAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ARGININE; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PROGNOSIS;

EID: 80055002137     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.021     Document Type: Article

References (36)

1. Sarkar R., Meinberg E.G., Stanley J.C., Gordon D., Webb R.C. Nitric oxide reversibly inhibits the migration of cultured smooth muscle cells. Circ Res 1996, 78:225-230.
2. Iràculis E., Cequier A., Gómez-Hospital J.A., et al. Early dysfunction and long-term improvement in endothelium dependent vaso-dilation in the infarct-related artery after thrombolysis. J Am Coll Cardiol 2002, 40:257-265.
3. Fichtlscherer S., Breuer S., Zeiher A.M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the " vulnerable" patient. Circulation 2004, 110:1926-1932.
4. Lundman P., Eriksson M.J., Stuhlinger M., et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001, 38:111-116.
5. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999, 33(April (4)):652-658.
6. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008, 51(January (2)):172-209.
7. Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000, 101(January (2)):125-130.
8. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996, 93(January (2)):223-228.
9. Iliceto S., Galiuto L., Marchese A., et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J 1997, 18:618-624.
10. Morishima I., Sone T., Mokuno S., et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995, 130(August (2)):239-243.
11. Morishima I., Sone T., Okumura K., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000, 36(October (4)):1202-1209.
12. Bae S.W., Stühlinger M.C., Yoo H.S., et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005, 95(March (6)):729-733.
13. Zeller M., Korandji C., Guilland J.C., et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol 2008, 28(May (5)):954-960.
14. Morrow D.A., Antman E.M., Charlesworth A., et al. TIMI risk score for ST-elevation myocard infarction: a convenient, bedside, clinical score for risk assessment at presentation. Circulation 2000, 102:2031-2037.
15. Chen B.M., Xia L.W., Zhao R.Q. Determination of N(G), N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997, 69(May (2)):467-471.
16. Anderson J.L., Karagounis L.A., Becker L.C., Sorensen S.G., Menlove R.L. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993, 87:1829-1839.
17. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996, 93(March (5)):879-888.
18. Schröder R., Dissmann R., Brüggemann T., et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994, 24(August (2)):384-391.
19. Gibson C.M., Karha J., Murphy S.A., et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003, 42(July (1)):7-16.
20. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
21. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
22. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88(November (10)):1201-1203.
23. Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007, 30:1834-1839.
24. Mittermayer F., Krzyzanowska K., Exner M., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006, 26(November (11)):2536-2540.
25. Zoccali C., Bode-Böger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358(December (9299)):2113-2117.
26. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97(September (5)):e53-e59.
27. Krempl T.K., Maas R., Sydow K., et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005, 26(September (18)):1846-1851.
28. Cavusoglu E., Ruwende C., Chopra V., et al. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis 2009, 20(March (2)):112-117.
29. Yokoyama M. Oxidant stress and atherosclerosis. Curr Opin Pharmacol 2004, 4:110-115.
30. Blake G.J., Ridker P.M. C-reactive protein and other infl{ligature}ammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003, 41:37S-42S.
31. Chalikias G.K., Tziakas D.N., Kaski J.C., et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 2005, 182(September (1)):135-143.
32. Kilic T., Ural D., Ural E., et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart 2006, 92(August (8)):1041-1046. [Epub 2006 Mar 17].
33. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dim-ethylaminohydrolase. Circulation 1999, 99:3092-3095.
34. Wang Q.D., Morcos E., Wiklund P., Pernow J. l-Arginine enhances functional recovery and Ca(2)-dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart. J Cardiovasc Pharmacol 1997, 29:291-296.
35. Gibson C.M., Murphy S.A., Kirtane A.J., et al. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004, 44(September (5)):980-987.
36. Aukrust P., Berge R.K., Ueland T., et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001, 37(February (2)):485-491.